| Source: |
Insect Cell |
| Molecular Weight: |
The apparent molecular weight is about 30 kDa in SDS-PAGE under reducing conditions, containing 237 amino acids. |
| AA Sequence: |
DEAIHCPPCS EEKLARCRPP VGCEELVREP GCGCCATCAL GLGMPCGVYT PRCGSGLRCY PPRGVEKPLH TLMHGQGVCM ELAEIEAIQE SLQPSDKDEG DHPNNSFSPC SAHDRRCLQK HFAKIRDRST SGGKMKVNGA PREDARPVPQ GSCQSELHRA LERLAASQSR THEDLYIIPI PNCDRNGNFH PKQCHPALDG QRGKCWCVDR KTGVKLPGGL EPKGELDCHQ LADSFRE |
| Purity: |
> 97% by SDS-PAGE and HPLC analyses. |
| Biological Activity: |
Fully biologically active when compared to standard. The ED50 as determined by its ability to inhibit IGF-II induced proliferation of MCF-7 cells is less than 0.1 μg/mL, corresponding to a specific activity of > 1.0 × 104 IU/mg in the presence of 14 ng/mL of rHuIGF-II. |
| Physical Appearance: |
Sterile filtered white lyophilized (freeze-dried) powder. |
| Formulation: |
Lyophilized from a 0.2 μm filtered concentrated solution in 20 mM Tris-HCl, pH8.0, 150 mM NaCl. |
| Endotoxin: |
Less than 0.1 EU/μg of rHuIGF-BP4, Insect Cell as determined by LAL method. |
| Background: |
IGFBP-4 (insulin-like growth factor binding protein 4) is a member of the IGFBP family, a group of structurally similar secreted glycoproteins that regulate the circulation of IGF-I and IGF-II, directing them to their target tissues. These binding proteins extend the half-life of IGFs and can either enhance or suppress the growth-promoting effects of IGFs on cells in culture. They modify the interaction between IGFs and their cell surface receptors. IGFBP-4 has been shown to consistently inhibit the growth of various cancer cells both in vitro and in vivo. |
